Biodesix (BDSX) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue increased 51% year-over-year to $17.9 million, marking eight consecutive quarters of over 40% revenue growth, driven by strong performance in lung diagnostics and biopharma services.

• Net loss improved by 19% to $10.8 million, reflecting higher gross margins and revenue growth; Adjusted EBITDA loss improved by 38% year-over-year.

• Raised $51.3 million in net proceeds from an oversubscribed public offering and private placement in April 2024, strengthening liquidity.

• Cash and cash equivalents stood at $42.2 million as of June 30, 2024, up $30.7 million from March 31, 2024.

• Recognized for workplace excellence, named to Inc. Magazine's 2024 Best Workplaces.

Financial highlights

• Q2 2024 total revenue was $17.9 million, up 51% year-over-year and 21% sequentially.

• Lung diagnostic revenue reached $16.5 million from 13,900 tests, up 44% in revenue and 42% in test volumes year-over-year.

• Biopharma Services revenue was $1.4 million, up 228% year-over-year.

• Gross margin was 78.4%, up 5.7 percentage points from Q2 2023 and consistent with Q1 2024.

• Operating expenses (excluding direct costs) increased 14% year-over-year to $22.3 million, mainly due to higher sales and marketing costs and increased depreciation.

Outlook and guidance

• 2024 revenue guidance raised to $70–$72 million from previous $65–$68 million, reflecting strong first-half results and confidence in the second half.

• Gross margins expected to remain steady in the upper 70s.

• Management expects continued operating losses in the near term as investments in growth and innovation persist.

• No significant improvements in reimbursement or additional coverage policies are built into guidance, maintaining a conservative approach.

• Ability to maintain financial covenants and execute the operating plan is critical to ongoing liquidity; further cost reductions or capital raises may be needed if targets are not met.